Aegis Therapeutics to Present Intravail(TM) Drug Delivery Technology at CBI's 'Protein Drugs' Conference.

SAN DIEGO -- Aegis Therapeutics, a leader in intranasal and transmucosal delivery of peptide, protein, and non-protein macromolecular drugs, today announced that Edward T. Maggio, Ph.D., President and Chief Executive Officer, will present an overview of recent advances in nasal delivery of peptide and protein drugs, including Aegis' Intravail(TM) non-invasive drug technology at the upcoming CBI conference entitled: "Protein Drugs: Scientific Strategies for Increasing Efficacy, Safety and Convenience in the Next Generation of Therapeutics" to be held January 19-20, 2006 in Philadelphia, PA.

Maggio commented: "Advances in non-invasive delivery of protein therapeutics will provide a highly attractive strategy that innovative biotechnology and pharmaceutical companies can employ to capture an increasing share of the estimated $70 billion market for protein therapeutics projected by 2008. Aegis business strategy is to broadly enable intranasal and transmucosal delivery of peptide and protein drugs for the world's current and future leading pharmaceutical and biopharmaceutical companies."

Information about the conference may be obtained from the CBI website at: http://www.cbinet.com/show_conference.cfm?confCode=HB615

About Aegis Therapeutics

Aegis Therapeutics LLC is a specialty pharmaceutical company commercializing its patented Intravail(TM) drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail(TM) absorption enhancement agents are mild and non-irritating to mucosal membranes. They provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal and other mucosal membrane administration routes. Intravail(TM) also provides for rapid drug absorption and onset of action, controlled transient permeation of the nasal mucosal barrier, avoidance of gastric hydrolysis and "first pass effect" elimination by the liver, greater patient convenience and compliance, elimination of needle-stick injuries and associated transmission of blood borne pathogens, compatibility with current nasal delivery devices, and ease of formulation, scale-up, and production. For more information about Aegis, please visit the Aegis website at: http://www.aegisthera.com.